Stephen Thomas, Ph.D.
Board Member
Stephen currently serves as CEO and director of Sera Medicines and Starfish Medicines, and brings broad experience in drug discovery and development, business development, and capital raises. He was previously CEO and co-founder of Tenet Medicines, Inc. and served as CSO of ValenzaBio, Inc., a clinical-stage biotechnology company, up until its acquisition by ACELYRIN, INC. At ValenzaBio, Stephen led the successful development of three antibody pipeline programs in I&I from preclinical to clinical proof-of-concept, including the anti-IGF-1R monoclonal antibody lonigutamab, and served a pivotal role in overall corporate strategy and fundraisings. Prior to ValenzaBio, Stephen was CSO and co-founder of Ichorion Therapeutics, Inc., where he built and advanced a pipeline of therapies for rare pediatric diseases up until its acquisition by Cerecor, Inc.
Dr. Thomas holds a Ph.D. in organic synthesis and chemical biology from Columbia University, where he was a Bristol-Myers Squibb Fellow and NSF Predoctoral Fellow, and was previously an Amgen Scholar.